September 7, 2006
Taisho Pharmaceutical Co., Ltd. [Headquarters: Toshima-ku, Tokyo, Japan; President: Akira Uehara] (hereinafter, Taisho) and Tokuhon Corporation [Headquarters: Chuo-ku, Tokyo, Japan; President: Kuniyuki Suzuki] (hereinafter, Tokuhon) have signed a basic agreement to collaborate in the development and sales of an anti-inflammatory analgesic patch formulation that contains the ingredient S-flurbiprofen. This analgesic patch formulation is currently being developed by Tokuhon.
Non-clinical trials have confirmed that this S-flurbiprofen patch formulation possesses a powerful analgesic effect, and the Phase 1 trials confirmed good skin permeability. The drug is expected to be highly therapeutically effective as a next-generation topical anti-inflammatory analgesic adhesive formulation. Tokuhon is currently conducting Phase 2 clinical trials to obtain approval for indications for osteoarthritis, scapulohumeral periarthritis, myalgia and other conditions. Taisho and Tokuhon will now collaborate on the joint development of the drug in Japan, with sales to be handled by Taisho Toyama Pharmaceutical Co., Ltd. [Headquarters: Toshima-ku, Tokyo, Japan; President: Akira Ohira], a subsidiary of Taisho.
Taisho is a leading self-medication (non-prescription) pharmaceutical company in Japan, and has also been focusing on its prescription drugs business. To this end, Taisho has been proactively forming collaborations with domestic and foreign pharmaceutical companies. In particular, Taisho's collaboration with Tokuhon will further strengthen the franchises Taisho has established in the areas of infectious, inflammatory and immunologic diseases.
Tokuhon is a pharmaceutical manufacturer specializing in the research and development, manufacture and sales of topical drugs. On the market since 1933, the company's stick-on anti-inflammatory analgesic "Tokuhon" has become well established in Japan as a non-prescription treatment for shoulder stiffness and backache. In its prescription drugs business, Tokuhon has been forming collaborations with domestic and foreign pharmaceutical companies to proactively conduct research and development in such drugs as new topical anti-inflammatory analgesics and new skin absorption treatment systems. The current agreement with Taisho will accelerate these activities.